Alyeska Investment Group L.P. Sells 60,930 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX)

Posted by Lauren Steadman on May 7th, 2025

Alyeska Investment Group L.P. lessened its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 6.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 859,083 shares of the company’s stock after selling 60,930 shares during the period. Alyeska Investment Group L.P. owned about 0.05% of Unity Biotechnology worth $839,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC increased its position in Unity Biotechnology by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 163,242 shares of the company’s stock valued at $240,000 after purchasing an additional 14,199 shares during the period. Hedge funds and other institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Stock Performance

Shares of UBX stock opened at $0.92 on Wednesday. The firm has a market capitalization of $15.84 million, a P/E ratio of -0.70 and a beta of 1.28. Unity Biotechnology, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $3.10. The stock’s fifty day moving average is $1.24 and its two-hundred day moving average is $1.41.

Unity Biotechnology (NASDAQ:UBX – Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). On average, equities analysts forecast that Unity Biotechnology, Inc. will post -1.45 earnings per share for the current year.

Analyst Ratings Changes

UBX has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Unity Biotechnology in a report on Wednesday, April 23rd. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of Unity Biotechnology in a research report on Wednesday, April 23rd.

Get Our Latest Research Report on Unity Biotechnology

About Unity Biotechnology

(Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.